Table 2.

Culture Results and Treatment Regimens of the Study Population.^a

Microbiology Results and Treatment Regimens
			Culture Results			Treatment
Patient	Age	Gender	Aerobic	Fungal	AFB	Antibiotic	No. of Courses/Total Duration
1	55	M	MSSA	Negative	Negative	TMP-SMX	1/180 d
2	86	M	Pseudomonas	Positive	NA	Ciprofloxacin	1/21 d
3	56	M	MSSA	Negative	NA	None	Patient lost to follow-up
4	70	M	MRSA	Negative	Negative	TMP-SMX	3/215 d
5	40	M	MSSA	Negative	NA	TMP-SMX	4/192 d
6	63	M	MSSA	Negative	NA	TMP-SMX	2/261 d
7	62	M	MSSA	Negative	NA	TMP-SMX	3/171 d
8	46	F	“Normal respiratory flora”	Negative	Negative	None	No treatment indicated
9	36	F	Serratia then MSSA	Negative	NA	Levofloxacin, TMP-SMX	1/14 d (L); 1/28 d (B)
10	66	M	MSSA	Negative	NA	TMP-SMX	1/90 d
11	38	F	MSSA	Negative	Negative	TMP-SMX	1/10 d
12	46	M	MSSA	Negative	Negative	TMP-SMX	Multiple at OSH
13	54	F	Serratia and MSSA	Negative	Negative	None	NA
14	69	F	MSSA	Negative	Negative	TMP-SMX	1/56 d
15	38	M	MSSA	Negative	Negative	Cephalexin	1/28 d

^aPatient No. 3 did not follow up after his biopsy for culture, so treatment was never initiated. Patient No. 9 initially had Serratia and was treated with levofloxacin (L). Repeat culture demonstrated only MSSA, and treatment consisted of TMP-SMX (B). Levofloxacin appeared to be successful in treating Serratia. Patient No. 11 was prescribed a longer course of antibiotics but stopped TMP-SMX early secondary to a rash. Patient No. 12 had multiple courses of TMP-SMX at an outside institution, but the exact duration was not available. The culture from Patient No. 13 grew Serratia and MSSA simultaneously. Patient No. 13 was evaluated by infectious disease, and the decision was made not to treat the culture results. Abbreviations: AFP, acid-fast bacteria; MRSA, Methicillin-resistant Staphylococcus aureus; MSSA, Methicillin-sensitive Staphylococcus aureus; OSH, outside hospital; TMP-SMX, trimethoprim-sulfamethoxazole or Bactrim.